Literature DB >> 11945173

Multiple activities in lantibiotics--models for the design of novel antibiotics?

U Pag1, H-G Sahl.   

Abstract

Lantibiotics are antibiotic peptides distinguished by the presence of the rare thioether amino acids lanthionine and/or methyllanthionine. They are produced by Gram-positive bacteria as gene-encoded precursor peptides and undergo post-translational modification to generate the mature peptide. The structural gene for the prepeptide and the genes involved in biosynthesis, processing, export as well as regulation and producer strain self-protection are organized in clusters. Based on their structural and functional features lantibiotics are currently divided into two major groups. The flexible amphiphilic type-A lantibiotics act primarily by pore formation in the bacterial membrane, a mechanism which was recently shown, e.g. for nisin and epidermin, to involve the interaction with specific docking molecules such as the membrane precursor lipid II. The rather rigid and globular type-B lantibiotics inhibit enzyme functions through interaction with the respective substrates: mersacidin and actagardine inhibit the cell wall biosynthesis by complexing lipid II, whereas the cinnamycin-like peptides inhibit phospholipases by binding phosphoethanolamine. Lantibiotics have attracted much attention in recent years and undergone extensive characterization. New insights into the mode of action and structure-function relationships as well as the biochemistry and the genetics will be outlined in this review.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11945173     DOI: 10.2174/1381612023395439

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  38 in total

1.  Synthesis of pdCpAs and transfer RNAs activated with thiothreonine and derivatives.

Authors:  Shengxi Chen; Nour Eddine Fahmi; Ryan C Nangreave; Youcef Mehellou; Sidney M Hecht
Journal:  Bioorg Med Chem       Date:  2012-02-15       Impact factor: 3.641

2.  Effect of lantibiotic gallidermin against biogenic amine-producing faecal staphylococci from ostriches and pheasants.

Authors:  Andrea Lauková; Anna Kandričáková; Pavel Pleva; Leona Buňková; Jana Ščerbová
Journal:  Folia Microbiol (Praha)       Date:  2017-01-13       Impact factor: 2.099

3.  The lantibiotic mersacidin is an autoinducing peptide.

Authors:  Stephanie Schmitz; Anja Hoffmann; Christiane Szekat; Brian Rudd; Gabriele Bierbaum
Journal:  Appl Environ Microbiol       Date:  2006-09-15       Impact factor: 4.792

Review 4.  Bacteriocin diversity in Streptococcus and Enterococcus.

Authors:  Ingolf F Nes; Dzung B Diep; Helge Holo
Journal:  J Bacteriol       Date:  2006-11-10       Impact factor: 3.490

5.  Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins.

Authors:  Máire Begley; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Appl Environ Microbiol       Date:  2009-06-26       Impact factor: 4.792

6.  Lantibiotic transporter requires cooperative functioning of the peptidase domain and the ATP binding domain.

Authors:  Mami Nishie; Makoto Sasaki; Jun-ichi Nagao; Takeshi Zendo; Jiro Nakayama; Kenji Sonomoto
Journal:  J Biol Chem       Date:  2011-02-08       Impact factor: 5.157

7.  Investigating the importance of charged residues in lantibiotics.

Authors:  Srinivas Suda; Colin Hill; Paul D Cotter; R Paul Ross
Journal:  Bioeng Bugs       Date:  2010 Sep-Oct

Review 8.  Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.

Authors:  Lindsay M Repka; Jonathan R Chekan; Satish K Nair; Wilfred A van der Donk
Journal:  Chem Rev       Date:  2017-01-30       Impact factor: 60.622

Review 9.  The dual role of bacteriocins as anti- and probiotics.

Authors:  O Gillor; A Etzion; M A Riley
Journal:  Appl Microbiol Biotechnol       Date:  2008-10-14       Impact factor: 4.813

10.  Discovery of unique lanthionine synthetases reveals new mechanistic and evolutionary insights.

Authors:  Yuki Goto; Bo Li; Jan Claesen; Yanxiang Shi; Mervyn J Bibb; Wilfred A van der Donk
Journal:  PLoS Biol       Date:  2010-03-23       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.